Successful treatment of metastatic mucosal melanoma with a Del579 c‐KIT mutation by imatinib after treatment of anti‐PD‐1 antibody

C-KIT mutations and amplifications are seen in approximately 15 to 30% of acral and mucosal melanomas. As c-KIT is a validated therapeutic target in other cancers, such as gastrointestinal stromal tumor (GIST) and chronic myelogenous leukemia (CML), there are several reports of melanoma patients with c-KIT mutation achieving good response to the off-label use of multi-tyrosine kinase inhibitors such as imatinib. The improved efficacy of sequential treatment with immunotherapies including programmed cell death1 (PD-1) blockade is currently being investigated. This article is protected by copyright. All rights reserved.